Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-HYPERTENSION: Orforglipron in Hypertension and Obesity
NCT06948422Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in hypertension (HTN) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Allocated to Each ISA. Started Apr 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06948422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948422.